Wyeth has acquired Thiakis Limited, a privately held biotechnology company based in the United Kingdom. Thiakis’ lead product candidate, TKS1225, is being studied for the treatment of medical obesity and other co-morbidities. TKS1225 and related compounds are synthetic versions of the natural gastrointestinal peptide oxyntomodulin. Wyeth is paying approximately $30 million for Thiakis, with potential milestone payments of as much as $120 million. Thiakis was founded in 2004. “T...